XenoPort, GlaxoSmithKline deal

XenoPort disclosed in its 4Q11 earning that it received a $5 million milestone payment from GlaxoSmithKline under an amended 2007 deal granting the pharma U.S. rights to Horizant gabapentin enacarbil extended-release tablets. The milestone was triggered after FDA accepted an sNDA from GSK for the extended-release formulation of the transported prodrug of gabapentin to treat post-herpetic neuralgia (PHN). The PDUFA date is June 9. The drug is already approved in the U.S. to treat restless legs syndrome (RLS) (see BioCentury, Oct. 31, 2011). ...